Age-related Macular Degeneration Market Analysis

Type (Wet AMD, Dry AMD)

In terms of type, the wet age-related macular degeneration market is anticipated to hold the highest CAGR of 80% during forecast period 2024-2036. Age-related macular degeneration is the beginning of the normal development of blood vessels below the retina. As AMD is the most common cause of significant loss of vision in people over the age of 50, the growing population around the world is creating a high level of demand in the market for wet age-related macular degeneration. In the next few years, East and Southeast Asia are expected to have the greatest increase of about 312 million people as indicated in the United Nations World Ageing Report 2019. In addition, approximately 200 million people over the age of 65 live in North America and Europe in 2019. These figures demonstrate that, all over the world, there will be a strong demand for therapies to treat age related macular degeneration in the future.

Application (Hospital, Clinic, Research Institute)

In terms of application, the hospital segment in the global age-related macular degeneration market is set to hold the highest CAGR of 60% by the end of 2036. The increase in the incidence of age-related macular degeneration and hospitalization for treatment may account for this dominant position. Various medicines, such as Lucentis, Eylea, and Beovu, administered intravenously under the supervision of experienced physicians in hospitals, are used to treat most patients. Therefore, hospital visits are expected to increase as a result of the growing demand for AMD treatment and this is likely to drive the market.

Our in-depth analysis of the global market includes the following segments: